tiakis Biotech

Executive Summary

Tiakis Biotech AG is a German biotechnology company developing tissue-protective therapeutics for diseases with high unmet medical need. Founded in 2020 and based in Berlin, the company leverages over 20 years of clinical research to harness the body's natural defense mechanisms. Its lead asset, Tiprelestat, is a clinical-stage disease-modifying therapy targeting pulmonary arterial hypertension (PAH) and the prevention of postoperative inflammatory complications. PAH is a progressive condition with limited treatment options, and Tiprelestat's novel mechanism offers potential to modify disease progression rather than just symptoms. In the postoperative setting, inflammatory complications remain a major cause of morbidity, and Tiprelestat aims to reduce these events through tissue-protective effects. As a private company, Tiakis has not disclosed funding rounds or valuation, but its clinical-stage asset positions it for upcoming value inflection points. The company's pipeline is highly focused on Tiprelestat, with potential for expansion into other inflammatory or fibrotic indications. Given the strength of its scientific foundation and the high unmet need in PAH, Tiakis represents an early-stage investment opportunity with significant upside but also inherent clinical and regulatory risks. The company's progress in advancing Tiprelestat through clinical trials will be key to its near-term trajectory.

Upcoming Catalysts (preview)

• H2 2026Tiprelestat Phase 2 top-line data in PAH50% success
• H1 2027Tiprelestat Phase 2 data in postoperative inflammatory complications40% success
• 2026Series A or B financing round60% success